AbbVie: adjusted EPS guidance raised for 2024

(CercleFinance.com) - AbbVie reports Q3 sales of $14.
46bn, up almost 4% from $13.92bn a year ago.

Net income attributable to equity holders of the parent came to $1,561m, compared with $1,778m in Q3 2023, i.e. EPS down from $1 to $0.88.

Adjusted EPS came to $3, just up from $2.95 a year earlier.

Against this backdrop, AbbVie has raised its adjusted EPS guidance for 2024 from $10.67 to $10.87 to $10.90 to $10.94, despite an unfavourable impact of $0.64 per share related to acquired R&D expenses and milestones incurred since the beginning of the year through to Q3 2024.

We have delivered another quarter of strong commercial execution and significant progress in our pipeline, AbbVie analyzes.

Given the momentum of AbbVie's business and our confidence in long-term growth prospects, we are again raising our full-year guidance and increasing our quarterly dividend. The dividend will rise from $1.55 to $1.64.

AbbVie has also announced a 5.8% increase in its 2025 dividend.


Copyright (c) 2024 CercleFinance.com. All rights reserved.